QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments
QUANTRO Therapeutics, a Spin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all pre-set goals for technical proof-of-concept, cross-validation of HTS screening technology and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished.
For many cancer patients there are no or only limited treatment options, which is why cancer remains to be a leading cause of death worldwide, accounting for nearly one in six deaths. Transcription factors have emerged as a promising class of therapeutic targets to address currently undruggable cancers. Transcription factors are central regulators of gene expression that are commonly dysregulated in cancer and have remained largely unamenable to pharmacological intervention. The joint R&D program, which was initiated in 2022, aims at changing the implied status quo via development of transformational, first-in-class cancer treatments.
Michael Bauer, CEO of QUANTRO, commented: “We are committed to drive a positive change for people affected by cancer, and to that end are looking forward to developing new mode of action compounds jointly with Boehringer Ingelheim. In reaching this milestone, QUANTRO Therapeutics continues to advance its leading transcriptomic R&D platform to build a highly innovative pipeline of modulators, inhibitors or degraders of transcription factors, transcriptional regulators and cell signaling targets.“
Norbert Kraut, Global Head of Cancer Research at Boehringer Ingelheim said: “We are excited and encouraged to see a very convincing and robust technology proof of concept, and highly attractive hits from the first screening that we can directly take to the next discovery and development stages. We look forward to further expanding our pipeline of first-in-class treatments to address the remaining high unmet patient need in cancer in partnership with QUANTRO.”
Upon accomplishment of this milestone, QUANTRO will receive an undisclosed milestone payment in addition to previously received upfront payments and R&D funding. The total potential transaction value may exceed EUR 500 million in form of R&D funding and success driven discovery, development, regulatory and commercial milestones.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
